npj Parkinsons Disease

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	216
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism	128
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	127
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	123
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	118
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	101
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	101
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	97
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	97
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	97
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	95
Differences in brain aging between sexes in Parkinson’s disease	93
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	93
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	81
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease	81
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	78
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	76
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	72
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	66
A versatile computational algorithm for time-series data analysis and machine-learning models	65
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	65
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission	64
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	63
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	63
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	63

EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	61
Redefining the hypotheses driving Parkinson’s diseases research	60
Advanced brain aging in Parkinson’s disease with cognitive impairment	60
The experience of Anxiety for people with Parkinson’s disease	59
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	57
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	57
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	56
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	55
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	54
Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson’s disease	53
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	53
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	53
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	53
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia	52
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis	52
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease	51
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	51
Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality	49
Enrichment of gut-derived metabolites in a Parkinson’s disease subtype with REM sleep behavior disorder	48
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach	46
Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling	46
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	45
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	44
In memorium, Michael Zigmond, PhD	44
A systematic review and meta-analysis of the prevalence of Parkinson’s disease in lower to upper-middle-income countries	43
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease	43
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus	43
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder	43
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism	42
Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?	42
Mechanisms of peripheral levodopa resistance in Parkinson’s disease	42
Immunological shifts during early-stage Parkinson’s disease identified with DNA methylation data on longitudinally collected blood samples	42
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease	41
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	41
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	40
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease	40
Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes	39
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis	39
A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease	39
Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson’s disease	38
Parkinson’s disease clinical milestones and mortality	38
Synuclein phosphorylation: pathogenic or physiologic?	38
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway	37
Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies	37
Associations of digestive diseases exposure and lifestyle factors with Parkinson’s disease	37
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	37
High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy	36
Increased frontal [123I]FP-CIT binding in Parkinson’s disease patients with self-reported REM sleep behavior disorder	36
Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson’s disease subtypes	36
Efficacy of deep brain stimulation of the subthalamic nucleus versus globus pallidus internus on sensory complaints	35

MAPKAPK2, a potential dynamic network biomarker of α-synuclein prior to its aggregation in PD patients	35
Hyposmia in Parkinson’s disease; exploring selective odour loss	35
Longitudinal multi-omics in alpha-synuclein Drosophila model discriminates disease- from age-associated pathologies in Parkinson’s disease	35
Personality profile and its association with conversion to neurodegenerative disorders in idiopathic REM sleep behavior disorder	35
Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson’s disease	34
Modulatory effect of levodopa on the basal ganglia-cerebellum connectivity in Parkinson’s disease	34
A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic	33
Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids	33
Peripheral inflammation’s variable impact on cognitive and symptomatic outcomes in Parkinson’s disease: a longitudinal and cross-sectional analysis	33
Analysis of striatal connectivity corresponding to striosomes and matrix in de novo Parkinson’s disease and isolated REM behavior disorder	33
A framework for translational therapy development in deep brain stimulation	32
Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson’s disease	31
Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson’s disease	31
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers	31
Digital phenotyping of Parkinson’s disease via natural language processing	30
Predictors of stress resilience in Parkinson’s disease and associations with symptom progression	30
Oral health implications in Parkinson’s disease	30
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months	29
Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy	28
Antagonistic network signature of motor function in Parkinson’s disease revealed by connectome-based predictive modeling	28
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	28
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases	28
Possible role of lncRNAs in amelioration of Parkinson’s disease symptoms by transplantation of dopaminergic cells	28
STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson’s disease	28
PDCD4 triggers α-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson’s disease	28
Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes	27
Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease	27
Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons	27
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)	27
Sleep disorders in Parkinson’s disease, an early and multiple problem	27
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies	26
Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease	26
Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease	26
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease	26
Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism	26
Towards scalable screening for the early detection of Parkinson’s disease: validation of an iPad-based eye movement assessment system against a clinical-grade eye tracker	25
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study	25
Mendelian randomization reveals association between retinal thickness and non-motor symptoms of Parkinson’s disease	25
Lipid profiling of Parkinson’s disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism	25
Time to workforce exit after a Parkinson’s disease diagnosis	25
Exploring the link between essential tremor and Parkinson’s disease	25
Arm swing responsiveness to dopaminergic medication in Parkinson’s disease depends on task complexity	25
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease	24
Modified version of unified multiple system atrophy rating scale for remote video-based assessments	24
Sentence completion in progressive supranuclear palsy following transcranial direct current stimulation	24
Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson’s disease	24
Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease	24
Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools	24
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease	24
Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory	24
Association of glymphatic system function with peripheral inflammation and motor symptoms in Parkinson’s disease	24
The effect of pallidal stimulation on sleep outcomes and related brain connectometries in Parkinson’s disease	23
Spatial variations and precise location of substantia nigra hyperechogenicity in Parkinson’s disease using TCS-MR fusion imaging	23
Brain-clinical biotyping in patients with idiopathic REM sleep behavior disorder	23
Subthalamic nucleus input-output dynamics are correlated with Parkinson’s burden and treatment efficacy	23
A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease	23
Misfolded protein deposits in Parkinson’s disease and Parkinson’s disease-related cognitive impairment, a [11C]PBB3 study	22
EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder	22
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies	22
Microstructural but not macrostructural cortical degeneration occurs in Parkinson’s disease with mild cognitive impairment	22
Central biogenic amine deficiency with concomitant exploratory behavioral deficits in Dnajc12 knock-out mice	22
Lack of full sequencing GBA1 studies for patients with Parkinson’s disease in Latin America	22
Glutamatergic synaptic resilience to overexpressed human alpha-synuclein	22
Neuropathology of Parkinson’s disease after focused ultrasound thalamotomy	22
α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies	22
Clinical subtypes in patients with isolated REM sleep behaviour disorder	22
A generalizable and open-source algorithm for real-life monitoring of tremor in Parkinson’s disease	21
The emerging postural instability phenotype in idiopathic Parkinson disease	21
Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages	21
Structural underpinnings and long-term effects of resilience in Parkinson’s disease	21
Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson’s disease	21
Genetically-informed prediction of short-term Parkinson’s disease progression	21
Intracellular α-synuclein assemblies are sufficient to alter nanoscale diffusion in the striatal extracellular space	21
Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease	21
Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson’s disease	20
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies	20
Prevalence of experienced changes in artistic and everyday creativity in people with Parkinson’s disease	20
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease	20
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein	20
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits	20

Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination	20
Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson’s disease	20
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2	20
Optimization of cognitive assessment in Parkinsonisms by applying artificial intelligence to a comprehensive screening test	20
Population fraction of Parkinson’s disease attributable to preventable risk factors	19
Author Correction: Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	19
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy	19
A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population	19
Different effect of hypo- and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent?	19
Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease	19
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity	19
A systematic review of brain morphometry related to deep brain stimulation outcome in Parkinson’s disease	19
Advancements in invasive and non-invasive neuromodulation for Parkinson’s disease: current findings and future directions	19
Subthalamic nucleus deep brain stimulation alleviates oxidative stress via mitophagy in Parkinson’s disease	19
Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects	19
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease	19
Modulation of subthalamic beta oscillations by movement, dopamine, and deep brain stimulation in Parkinson’s disease	19
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	18
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	18
Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia	18
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	18
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	18
Neurocognitive correlates of semantic memory navigation in Parkinson’s disease	18
Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson’s disease	18
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice	18
Baseline cerebral structural morphology predict freezing of gait in early drug-naïve Parkinson’s disease	18
Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review	17
White matter and nigral alterations in multiple system atrophy-parkinsonian type	17
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease	17
Towards a methodological uniformization of environmental risk studies in Parkinson’s disease	17
Prominent role of PM10 in the link between air pollution and incident Parkinson’s Disease	17
Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease	17
Effects of deep brain stimulation frequency on eye movements and cognitive control	17
MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches	17
Exploring glymphatic system alterations in iRBD and Parkinson’s disease using automated DTI-ALPS analysis	17
The barriers to receiving health care for people with Parkinson’s from predominantly Asian backgrounds in the UK	17
High-resolution mapping of substantia nigra in Parkinson’s disease using 7 tesla magnetic resonance imaging	17
Social isolation and the risk of Parkinson disease in the UK biobank study	17
Atrophy of ventral diencephalon is associated with freezing of gait in Parkinson’s disease: analysis of two cohorts	17
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients	17
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies	17
A single centre prospective study of three device-assisted therapies for Parkinson’s disease	17
Different risks of early-onset and late-onset Parkinson disease in individuals with mental illness	17
Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition	17
AccessPD as a next generation registry to accelerate Parkinson’s disease research	16
Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD	16
Genetic analyses identify circulating genes related to brain structures associated with Parkinson’s disease	16
Regional-specific structural and functional changes of posterior cerebellar vermis across different stages of Parkinson’s disease with gait dysfunction	16
Cerebral perfusion imaging predicts levodopa-induced dyskinesia in Parkinsonian rat model	16
Advancing age and the rs6265 BDNF SNP are permissive to graft-induced dyskinesias in parkinsonian rats	16
Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson’s disease	16
Author Correction: The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data	16
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	16
Association between Parkinson’s disease and the faecal eukaryotic microbiota	16
Single-cell RNA sequencing reveals peripheral immunological features in Parkinson’s Disease	16
Simulating the progression of brain structural alterations in Parkinson’s disease	15
Modulation of DBS-induced cortical responses and movement by the directionality and magnitude of current administered	15
Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology	15
Participant-reported personal utility of genetic testing for Parkinson’s disease and interest in clinical trial participation	15
Strain-specific effects of Desulfovibrio on neurodegeneration and oxidative stress in a Caenorhabditis elegans PD model	15
Electrophysiological approaches to informing therapeutic interventions with deep brain stimulation	15
Clinico-physiological correlates of Parkinson’s disease from multi-resolution basal ganglia recordings	15
Accelerating Parkinson’s Disease drug development with federated learning approaches	15
Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis	15
Disruption of axonal transport in Parkinson’s disease: the role of pathological α-Syn and AMPK/p38 MAPK signaling	15
Subthalamic stimulation evokes hyperdirect high beta interruption and cortical high gamma entrainment in Parkinson’s disease	15
GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate	15
Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson’s disease	15
Deep brain stimulation rectifies the noisy cortex and irresponsive subthalamus to improve parkinsonian locomotor activities	15
Synthetic MRI study of brain volume and subcortical myelin in various Parkinson’s disease motor subtypes	15